How To Play Cellular Biomedicine Group Inc. (NASDAQ:CBMG)?


Here is an analysis at the scorecard of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) for the recent quarter and analyst projections for the coming periods.

The firm generated sales of 98,425%, implying a jump of -3.98% compared to a analogous quarter a year ago.

To achieve the recorded sales of 98,425% for the quarter, the firm incurred $707,141 in cost of goods. Hence, after considering the cost of sales, Cellular Biomedicine Group Inc. came with a gross income of $(608,716).

Let’s look into the technical of the stock

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

Cellular Biomedicine Group Inc. incurred other expenses in the completion of operation. Taking those into account, it closed the quarter with EPS of $(0.43). The firm had 14.28M diluted outstanding shares at the close of the quarter.

For the next quarter, analysts on the average are projecting EPS of $-0.47.

Cellular Biomedicine Group Inc.’s cash balance at the close of the recent quarter was 33.36M%. The firm generated free cash flow of $(5.89M) during the quarter, while net operating cash flow was $(4.86M). Net change in cash was $(5.89M).

What is market thinking about Cellular Biomedicine Group Inc.? So far 1 analysts have assessed the stock, and they have average recommendation of Buy and average price target of $18.00. To put the recommendation into perspective, call in the range of 1.00 – 1.24 indicates a BUY recommendation, whereas 1.25 – 1.74 refers to OVERWEIGHT. HOLD recommendation is shown by 1.75 ? 2.24, UNDERWEIGHT is signified by 2.25 – 2.74 while SELL is signified by 2.75 – 3.00.

Does Cellular Biomedicine Group Inc. have a strong balance sheet? A look at the firm’s balance sheet at the close of the most recent quarter displays that it has total assets of $63.59M, offset by total liabilities of $2.37M.

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the Company’s Board of Directors (the “Board”) has approved a new stock repurchase program granting the company authority to repurchase up to $10 million in common shares (the “2017 Stock Repurchase Program”) through open market purchases pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.